Literature DB >> 26681217

Diagnostic values of microRNA-31 in peripheral blood mononuclear cells for pediatric pulmonary tuberculosis in Chinese patients.

J X Wang1, J Xu1, Y F Han1, Y B Zhu1, W J Zhang1.   

Abstract

We investigated the diagnostic values of microRNA-31 in peripheral blood mononuclear cells (PBMCs) for pediatric pulmonary tuberculosis in Chinese patients. Sixty-five children with TB were selected for this study, which was conducted at the Department of Infectious Diseases People's Hospital of Laiwu City between December 2013 and December 2014. Sixty healthy children, selected in parallel, served as the control group. Real-time PCR was used to detect miR-31 expression in PBMCs. Serum levels of IL-6, TNF-α, NF-κB, and IFN-γ was detected by ELISA. ROC curve was employed to evaluate the diagnostic value of miR-31 in pediatric TB. Results show that expression of miRNA-31 in pediatric TB patients was significantly lower than that in normal children (0.48 ± 0.15 vs 1.23 ± 0.36, P < 0.05). By contrast, serum levels of the innate immune response cytokines, IL-6, TNF-α, NF-κB, and IFN-γ, were significantly higher in pediatric TB patients compared with normal children (P < 0.05). Furthermore, miRNA-31 expression was negatively correlated with serum levels of IL-6 (t = 69.91, P < 0.001), TNF-α (t = 10.96, P < 0.001), NF-κB (t = 39.94, P < 0.001), and IFN -γ (t = 37.94, P < 0.001). The cut-off threshold of miR-31 for pediatric TB diagnosis is 0.835 with a sensitivity of 98.5% and a specificity of 86.7%. Therefore, miR-31 has the potential to be a diagnostic marker in pediatric TB patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26681217     DOI: 10.4238/2015.December.16.23

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  15 in total

Review 1.  Function and regulation of microRNA-31 in development and disease.

Authors:  Nadezda A Stepicheva; Jia L Song
Journal:  Mol Reprod Dev       Date:  2016-08-02       Impact factor: 2.609

2.  Expression levels of candidate circulating microRNAs in pediatric tuberculosis.

Authors:  Kathirvel M; Saranya S; Mahadevan S
Journal:  Pathog Glob Health       Date:  2020-05-13       Impact factor: 2.894

Review 3.  Epigenetic regulation of pediatric and neonatal immune responses.

Authors:  Jennifer Bermick; Matthew Schaller
Journal:  Pediatr Res       Date:  2021-07-08       Impact factor: 3.756

Review 4.  Non-Coding RNAs in Tuberculosis Epidemiology: Platforms and Approaches for Investigating the Genome's Dark Matter.

Authors:  Ahmad Almatroudi
Journal:  Int J Mol Sci       Date:  2022-04-17       Impact factor: 6.208

Review 5.  miRNAs in Tuberculosis: New Avenues for Diagnosis and Host-Directed Therapy.

Authors:  Naveed Sabir; Tariq Hussain; Syed Zahid Ali Shah; Antonio Peramo; Deming Zhao; Xiangmei Zhou
Journal:  Front Microbiol       Date:  2018-03-29       Impact factor: 5.640

6.  miRNAs reshape immunity and inflammatory responses in bacterial infection.

Authors:  Xikun Zhou; Xuefeng Li; Min Wu
Journal:  Signal Transduct Target Ther       Date:  2018-05-25

7.  Biomarkers for diagnosis of childhood tuberculosis: A systematic review.

Authors:  Toyin Omotayo Togun; Emily MacLean; Beate Kampmann; Madhukar Pai
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

8.  Small RNA Profiles of Serum Exosomes Derived From Individuals With Latent and Active Tuberculosis.

Authors:  Lingna Lyu; Xiuli Zhang; Cuidan Li; Tingting Yang; Jinghui Wang; Liping Pan; Hongyan Jia; Zihui Li; Qi Sun; Liya Yue; Fei Chen; Zongde Zhang
Journal:  Front Microbiol       Date:  2019-05-28       Impact factor: 5.640

Review 9.  Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers.

Authors:  Alessandro Sinigaglia; Elektra Peta; Silvia Riccetti; Seshasailam Venkateswaran; Riccardo Manganelli; Luisa Barzon
Journal:  Cells       Date:  2020-09-24       Impact factor: 6.600

Review 10.  Diagnosis for Latent Tuberculosis Infection: New Alternatives.

Authors:  Claudia Carranza; Sigifredo Pedraza-Sanchez; Eleane de Oyarzabal-Mendez; Martha Torres
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.